Ionis Pharmaceuticals, Inc. Share-based Payment Arrangement, Expensed and Capitalized, Amount
Ionis Pharmaceuticals, Inc. (IONS) reported Share-based Payment Arrangement, Expensed and Capitalized, Amount of $45.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Share-Based Payment Arrangement, Expensed and Capitalized, Amount
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-06-30 was $45.59M, a 50.98% increase year-over-year.
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2026-03-31 was $43.29M, a 43.31% increase year-over-year.
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-12-31 was $43.67M, a 19.85% increase year-over-year.
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for the quarter ending 2025-09-30 was $31.58M, a 2.80% decline year-over-year.
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2025 was $135.66M, a 3.56% increase from fiscal 2024.
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2024 was $131.00M, a 23.81% increase from fiscal 2023.
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2023 was $105.81M, a 5.53% increase from fiscal 2022.
- Ionis Pharmaceuticals, Inc. share-based payment arrangement, expensed and capitalized, amount for fiscal 2022 was $100.26M.
| Period end | Share-based Payment Arrangement, Expensed and Capitalized, Amount 3 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 6 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 9 month | Share-based Payment Arrangement, Expensed and Capitalized, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.59M 10-Q · filed 2026-07-29 | $88.89M 10-Q · filed 2026-07-29 | $132.56M derived: sum of 3 quarters · filed 2026-07-29 | $164.14M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $43.29M 10-Q · filed 2026-04-29 | $86.97M derived: sum of 2 quarters · filed 2026-04-29 | $118.55M derived: sum of 3 quarters · filed 2026-04-29 | $148.75M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $43.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $75.26M derived: sum of 2 quarters · filed 2026-02-26 | $105.45M derived: sum of 3 quarters · filed 2026-07-29 | $135.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | $31.58M 10-Q · filed 2025-10-29 | $61.78M derived: sum of 2 quarters · filed 2026-07-29 | $91.99M 10-Q · filed 2025-10-29 | $128.43M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $30.20M 10-Q · filed 2026-07-29 | $60.41M 10-Q · filed 2026-07-29 | $96.85M derived: sum of 3 quarters · filed 2026-07-29 | $129.34M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $30.21M 10-Q · filed 2026-04-29 | $66.65M derived: sum of 2 quarters · filed 2026-04-29 | $99.14M derived: sum of 3 quarters · filed 2026-04-29 | $129.87M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $36.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $68.93M derived: sum of 2 quarters · filed 2026-02-26 | $99.66M derived: sum of 3 quarters · filed 2026-02-26 | $131.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $32.49M 10-Q · filed 2025-10-29 | $63.22M derived: sum of 2 quarters · filed 2025-10-29 | $94.56M 10-Q · filed 2025-10-29 | $120.89M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $30.73M 10-Q · filed 2025-07-30 | $62.07M 10-Q · filed 2025-07-30 | $88.40M derived: sum of 3 quarters · filed 2026-02-26 | $114.37M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $31.34M 10-Q · filed 2025-04-30 | $57.68M derived: sum of 2 quarters · filed 2026-02-26 | $83.64M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $26.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $52.30M derived: sum of 2 quarters · filed 2026-02-26 | $105.81M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $25.96M 10-Q · filed 2024-11-06 | $79.47M 10-Q · filed 2024-11-06 | ||
| 2022-12-31 | $100.26M 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |